

## Synthesis, characterization and biological evaluation of *N*-(2,3-dimethyl-5-oxo-1-phenyl-2,5-dihydro-1*H*-pyrazol-4-yl)benzamides

Aamer Saeed<sup>a\*</sup>, Syeda Abida Ejaz<sup>b</sup>, Asma Khurshid<sup>a</sup>, Sidra Hassan<sup>b</sup>, Mariya al-Rashida<sup>c</sup>,  
Muhammad Latif<sup>d</sup>, Joanna Lecka<sup>e,f</sup>, Jean Sévigny<sup>e,f</sup> & Jamshed Iqbal<sup>b\*</sup>

<sup>a</sup> Department of Chemistry, Quaid-I-Azam University, 45320, Islamabad, Pakistan

<sup>b</sup> Centre for Advanced Drug Research, COMSATS Institute of Information Technology, Abbottabad 22060, Pakistan

<sup>c</sup> Department of Chemistry, Forman Christian College (A Chartered University), Ferozpur Road-54600, Lahore, Pakistan

<sup>d</sup> Medicinal/Pharmaceutical Chemistry Laboratory, Korea Research Institute of Chemical Technology 141-Gajeongro, Yuseong, Daejeon 305-600, South Korea.


<sup>e</sup> Département de microbiologie-infectiologie et d'immunologie, Faculté de Médecine, Université Laval, Québec, QC, Canada

<sup>f</sup> Centre de Recherche du CHU de Québec – Université Laval, Québec, QC, Canada


### SUPPORTING INFORMATION

List of Figures	Pg #
Spectral data, LCMS, GCMS	2-33
Figure S1. Ramachandran Plot of re5NT.	34
Figure S2. Ramachandran Plot of hTNALP.	35
Figure S3. Ramachandran Plot of hIALP.	36
Figure S4. Ramachandran Plot of hGCALP.	37
Figure S5. Sequence alignment of target rat ecto-5'-Nucleotidase (re5NT) with the template protein human ecto-5'-Nucleotidase (he5NT).	38
Figure S6. Sequence alignment of target human tissue non-specific alkaline phosphatase (hTNAP) with the template protein human placental alkaline phosphatase (hPALP).	39
Figure S7. Sequence alignment of target human intestinal alkaline phosphatase (hIALP) with the template protein human placental alkaline phosphatase (hPALP).	40
Figure S8. Sequence alignment of target human germ cell alkaline phosphatase (hGCALP) with the template protein human placental alkaline phosphatase (hPALP).	41
Table S1. Comparison of active site residues of hTNALP, hIALP and hGCALP with hPALP (PDB id: 1ZED). Conserved residues (with respect to hPALP) are in purple font color, the residues which are not conserved are in red font color.	42


**4a -<sup>1</sup>H-NMR a:**




**4a-<sup>13</sup>C-NMR a:**




**4a-<sup>13</sup>C-NMR-b:**



**4b-<sup>1</sup>H-NMR-a:**




**4b-<sup>1</sup>H-NMR-b:**






# 4b-<sup>13</sup>C-NMR-a:




**4b-<sup>13</sup>C-NMR-b:**









# 4c-<sup>13</sup>C-NMR-a:




# 4d-<sup>1</sup>H-NMR-a:




**4d-<sup>13</sup>C-NMRa:**



**4e-<sup>1</sup>H-NMR-a:**




**4e-<sup>13</sup>C-NMR-a:**







# 4f-<sup>1</sup>H-NMR-a:




# 4f-<sup>1</sup>H-NMR-b:



# 4f-<sup>13</sup>C-NMRa:




**4f-<sup>13</sup>C-NMR-b:**






**4g-<sup>13</sup>C-NMR-a:**









# 4h-<sup>13</sup>C-NMR-a:




# 4h-<sup>13</sup>C-NMR-b:



# 4i-<sup>1</sup>H-NMR-a:




**4i-<sup>1</sup>H-NMR-b:**






# 4i-<sup>13</sup>C-NMR-a:









# 4j-<sup>13</sup>C-NMR-a:




## 4a (LC/MS)



# 4b (GC/MS)




#### 4c (LC/MS)




#### 4d (LC/MS)




#### 4e (LC/MS)




## 4f (LC/MS)



## 4g (LC/MS)




## 4h (LC/MS)







#### 4i (LC/MS)




#### 4j (LC/MS)







**Figure S1.** Ramachandran Plot of re5NT, (A) General; (B) Isoleucine & Valine; (C) Pre-Proline; (D) Glycine. 96.5% (554/574) of all residues are in favored (98%) regions. 99.0% (568/574) of all residues are in allowed (>99.8%) regions.



**Figure S2.** Ramachandran Plot of hTNAP, (A) General; (B) Isoleucine & Valine; (C) Pre-Proline; (D) Glycine. 96.0% (459/478) of all residues are in favored (98%) regions. 98.5% (471/478) of all residues are in allowed (>99.8%) regions.




**Figure S3.** Ramachandran Plot of hIALP, (A) General; (B) Isoleucine & Valine; (C) Pre-Proline; (D) Glycine. 96.8% (509/526) of all residues are in favored (98%) regions. 99.4% (523/526) of all residues are in allowed (>99.8%) regions.



**Figure S4.** Ramachandran Plot of hGCALP, (A) General; (B) Isoleucine & Valine; (C) Pre-Proline; (D) Glycine. 97.9% (519/530) of all residues are in favored (98%) regions. 99.8% (529/530) of all residues are in allowed (>99.8%) regions.

RMSD: ca	1	11	21	31	41		
4H2I, chain A	26			MWE	LTILHTNDVH	SRLEQTSEDS	
Q66HL0_RAT model 4	1	MRPAAATAPK	WLLLLALSALL	PLWPTAK	SWE	LTILHTNDVH	SRLEQTSDDS
RMSD: ca	51	61	71	81	91		
4H2I, chain A	49	SKCVDASRCM	GGVARLFTKV	QQIRRAEPNV	LLLDAGDQYQ	GTIWFTVYKG	
Q66HL0_RAT model 4	51	TKCLNASLCV	GGVARLFTKV	QQIRKEEPNV	LLLDAGDQYQ	GTIWFTVYKG	
RMSD: ca	101	111	121	131	141		
4H2I, chain A	99	A EVAHF MNAL	RYDAMALGNH	EFDNGVEGLI	EPLLKEAKFP	ILSANIKAKG	
Q66HL0_RAT model 4	101	LEVAHF MNLL	GYDAMALGNH	EFDNGVEGLI	DPLL RNVKFP	ILSANIKARG	
RMSD: ca	151	161	171	181	191		
4H2I, chain A	149	PLASQISGLY	LPYKVLVPGD	E VVGIVGYTS	KETPFLSNPG	TNLVFEDEIT	
Q66HL0_RAT model 4	151	PLAPQISGLY	LPYKVLVSGG	E VVGIVGYTS	KETPFLSNPG	TNLVFEDEV T	
RMSD: ca	201	211	221	231	241		
4H2I, chain A	199	ALQPEVDK LK	TLNVNKI IAL	GHS GFEMDKL	IAQKVRGVDV	VVGGHSNTFL	
Q66HL0_RAT model 4	201	ALQPEVDK LK	TLNVNKI IAL	GHS GFEMDKL	IAQKVRGVDV	VVGGHTNTFL	
RMSD: ca	251	261	271	281	291		
4H2I, chain A	249	Y TGNPPSKEV	PAGKYPFIVT	SDDGRKVPV V	QAYAFGKYL G	Y LKIEFDERG	
Q66HL0_RAT model 4	251	Y TGNPPSKEV	PAGKYPFIVT	SDDGRKVPV V	QAYAFGKYL G	Y LKVEFDDK G	
RMSD: ca	301	311	321	331	341		
4H2I, chain A	299	NVIVSSHGNPI	LLDSSIPEDP	S I KADIN KWR	I KLD DYSTQE	L GKTIVYLDG	
Q66HL0_RAT model 4	301	NVVTSYGNPI	LLNSTIR EDA	A I KADIN QWR	I KLD NYSTQE	L GRTIVYLN G	
RMSD: ca	351	361	371	381	391		
4H2I, chain A	349	SSQSCRFR EC	NMGNLICDAM	INNNLRH ADE	MFWNHVSMCI	LNGGGIRSPI	
Q66HL0_RAT model 4	351	SAQE CRFR EC	NMGNLICDAM	INNNLRHPDE	MFWNHVSMCI	VNGGGIRSPI	
RMSD: ca	401	411	421	431	441		
4H2I, chain A	399	DERNDGTITW	ENLA AVL PFG	GTFDLVQLKG	STLKKAF EHS	VHRYGQSTGE	
Q66HL0_RAT model 4	401	DERNNGTITW	ENLA AVL PFG	GTFDLVQLKG	STLKKAF EHS	VHRYGQSTGE	
RMSD: ca	451	461	471	481	491		
4H2I, chain A	449	FLQVGGI HVV	Y DLSRKP GDR	VVKLDV LCTK	CRVPSYDPLK	MDEVYK VILP	
Q66HL0_RAT model 4	451	FLQVGGI HVV	Y DLSRKP WDR	VVQLKVLCTK	CRVPIYEPL E	MDKVYK VVLP	
RMSD: ca	501	511	521	531	541		
4H2I, chain A	499	NFLANGGDGF	QM I KDELLRH	D S G D Q D I N V V	S T Y I S K M K V I	Y P A V E G R I K F	
Q66HL0_RAT model 4	501	S Y L V N G G D G F	Q M I K D E L L K H	D S G D Q D I S V V	S E Y I S K M K V I	Y P A V E G R I K F	
RMSD: ca	551	561	571	581			
4H2I, chain A	549	S L E H H H H H H					
Q66HL0_RAT model 4	551	S . . . . . A	A S H Y Q G S F P L	I I L S F W A V I L	V L Y Q		

**Figure S5.** Sequence alignment of target rat ecto-5'-Nucleotidase (re5NT) with the template protein human ecto-5'-Nucleotidase (he5NT).




**Figure S6.** Sequence alignment of target human tissue non-specific alkaline phosphatase (hTNAP) with the template protein human placental alkaline phosphatase (hPALP).

	1	11	21	31	41
RMSD: ca					
1ZED, chain A	1		I	I	W
PPBI_HUMAN model 1	1		I	W	A
	51	61	71	81	91
RMSD: ca					
1ZED, chain A	32	A	A	K	D
PPBI_HUMAN model 1	51	A	A	K	D
	101	111	121	131	141
RMSD: ca					
1ZED, chain A	82	T	G	L	N
PPBI_HUMAN model 1	101	T	G	L	N
	151	161	171	181	191
RMSD: ca					
1ZED, chain A	132	V	Q	H	A
PPBI_HUMAN model 1	151	V	Q	H	A
	201	211	221	231	241
RMSD: ca					
1ZED, chain A	182	G	C	D	I
PPBI_HUMAN model 1	201	G	C	D	I
	251	261	271	281	291
RMSD: ca					
1ZED, chain A	232	N	L	V	Q
PPBI_HUMAN model 1	251	N	L	V	Q
	301	311	321	331	341
RMSD: ca					
1ZED, chain A	282	S	T	L	D
PPBI_HUMAN model 1	301	S	T	L	D
	351	361	371	381	391
RMSD: ca					
1ZED, chain A	332	I	M	F	D
PPBI_HUMAN model 1	351	I	M	F	D
	401	411	421	431	441
RMSD: ca					
1ZED, chain A	382	A	R	D	R
PPBI_HUMAN model 1	401	A	R	D	R
	451	461	471	481	491
RMSD: ca					
1ZED, chain A	432	H	A	G	E
PPBI_HUMAN model 1	451	H	A	G	E
	501	511	521	531	

**Figure S7.** Sequence alignment of target human intestinal alkaline phosphatase (hIALP) with the template protein human placental alkaline phosphatase (hPALP).





**Figure S8.** Sequence alignment of target human germ cell alkaline phosphatase (hGCAP) with the template protein human placental alkaline phosphatase (hPALP).

**Table S1.** Comparison of active site residues of hTNALP, hIALP and hGCALP with hPALP (PDB id: 1ZED). Conserved residues (with respect to hPALP) are in purple font color, the residues which are not conserved are in red font color.

<b>hPALP</b>	<b>hTNALP</b>	<b>hIALP</b>	<b>hGCALP</b>
Asp42	Asp43	Asp61	Asp61
Asp91	Asp92	Asp110	Asp110
Ser92	Ser93	Ser111	Ser111
Phe107	Glu108	Phe126	Phe126
Gln108	Gly109	Gln127	Gln127
His153	His154	His172	His172
Ser155	Thr156	Ser174	Ser174
Arg166	Arg167	Arg185	Arg185
Glu311	Glu315	Glu330	Glu330
Asp316	Asp320	Asp335	Asp335
His320	His324	His339	His339
Asp357	Asp361	Asp376	Asp376
His358	His362	His377	His377
Glu429	His434	Ser448	Gly448
His432	His437	His451	His451